Frankfurt
18.09.26 | 15:25
15,300 Euro
+3,38 % +0,500
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 13.08. | Fortress Biotech, Inc. - 10-Q, Quarterly Report | 14 | SEC Filings | ||
| 23.06. | Fortress Biotech, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 14.05. | Fortress Biotech, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 14.05. | Fortress Biotech GAAP EPS of $2.82, revenue of $16.04M misses by $0.3M | 4 | Seeking Alpha | ||
| 14.05. | Fortress Biotech, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| FORTRESS BIOTECH INC PREF Aktie jetzt für 0€ handeln | |||||
| 14.05. | Fortress Biotech, Inc.: Fortress Biotech Reports First Quarter 2026 Financial Results and Recent Corporate Highlights | 831 | GlobeNewswire (Europe) | ZYCUBO approved by FDA to treat Menkes disease in the United States; Fortress subsidiary Cyprium Therapeutics closed the sale of its Rare Pediatric Disease Priority Review Voucher (PRV) for $205 million... ► Artikel lesen | |
| 31.03. | Fortress Biotech GAAP EPS of -$0.07 misses by $0.39, revenue of $63.26M misses by $10.08M | 6 | Seeking Alpha | ||
| 31.03. | Fortress Biotech, Inc.: Fortress Biotech Reports 2025 Financial Results and Recent Corporate Highlights | 836 | GlobeNewswire (Europe) | ZYCUBOapproved by FDA to treat Menkes disease in the United States; Fortress subsidiary Cyprium Therapeutics sold its Rare Pediatric Disease Priority Review Voucher (PRV) for gross proceeds of $205... ► Artikel lesen | |
| 31.03. | Fortress Biotech, Inc. - 10-K, Annual Report | - | SEC Filings | ||
| 30.03. | Fortress Biotech, Inc.: Fortress Biotech's Subsidiary Cyprium Therapeutics Closes Sale of Rare Pediatric Disease Priority Review Voucher for $205 Million | 447 | GlobeNewswire (Europe) | MIAMI, March 30, 2026 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) ("Fortress") and its majority-owned subsidiary, Cyprium Therapeutics, Inc. ("Cyprium"), today announced the closing... ► Artikel lesen | |
| 23.02. | Fortress Biotech, Inc.: Fortress Biotech's Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million | 569 | GlobeNewswire (Europe) | MIAMI, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) ("Fortress") and its majority-owned subsidiary, Cyprium Therapeutics, Inc. ("Cyprium"), today announced that Cyprium... ► Artikel lesen | |
| 16.01. | Weekly Buzz: Lyra Therapeutics Slashes Jobs; FDA Okays Fortress Biotech's ZYCUBO; Boston Scientific To Acquire Penumbra; BriaCell Therapeutics On Watch | 1.005 | AFX News | NEW BRUNSWICK (dpa-AFX) - This week, the biotech sector saw a steady stream of high-impact news, including a major workforce reduction and a fresh round of regulatory clearances spanning diabetes... ► Artikel lesen | |
| 13.01. | Fortress Biotech, Inc.: Fortress Biotech and Cyprium Therapeutics Announce U.S. FDA Approval of ZYCUBO (copper histidinate), the First and Only Approved Treatment for Menkes Disease in the United States | 984 | GlobeNewswire (Europe) | Rare Pediatric Disease Priority Review Voucher (PRV) granted by FDA at approval to be transferred from Sentynl Therapeutics to Cyprium Cyprium eligible to receive tiered royalties and up to $129 million... ► Artikel lesen | |
| 14.11.25 | Fortress Biotech, Inc.: Fortress Biotech Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights | 981 | GlobeNewswire (Europe) | Total net revenue increased 20.5% to $17.6 million for third quarter of 2025 compared to the third quarter of 2024 Fortress subsidiary Checkpoint Therapeutics acquired by Sun Pharma; Fortress received... ► Artikel lesen | |
| 21.10.25 | Fortress Biotech, Inc.: Fortress Biotech and Subsidiary Urica Therapeutics Announce First Patients Dosed in Crystalys Therapeutics' Global Phase 3 Trials of Dotinurad for the Treatment of Gout | 425 | GlobeNewswire (Europe) | MIAMI, Oct. 21, 2025 (GLOBE NEWSWIRE) -- Urica Therapeutics, Inc. ("Urica" or the "Company"), a Fortress Biotech, Inc. (Nasdaq: FBIO) ("Fortress") subsidiary, today announced that Crystalys Therapeutics... ► Artikel lesen | |
| 01.10.25 | Fortress Biotech, Inc.: Fortress Biotech and Subsidiary Urica Therapeutics Announce Crystalys Therapeutics' $205 Million Series A Financing | 269 | GlobeNewswire (Europe) | Dotinurad is a next-generation URAT1 inhibitor in two Phase 3 clinical trials with potential for best-in-class safety and efficacy Urica sold dotinurad to Crystalys Therapeutics in 2024 in exchange... ► Artikel lesen | |
| 01.10.25 | Fortress Biotech, Inc.: Fortress Biotech and Cyprium Therapeutics Announce an Update on the NDA for CUTX-101 | 326 | GlobeNewswire (Europe) | MIAMI, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) ("Fortress") and its majority-owned subsidiary, Cyprium Therapeutics, Inc. ("Cyprium"), today announced that the U.S.... ► Artikel lesen |
17 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| STRYKER | 238,70 | -0,29 % | Stryker: Cyberangriff wirkt nach - das ist jetzt entscheidend | ||
| REGENERON PHARMACEUTICALS | 685,10 | +0,53 % | Regeneron auf Morgan Stanley Konferenz: Wachstum stützt sich auf Dupixent | ||
| VIKING THERAPEUTICS | 25,100 | -0,59 % | Wall Street Sees a Huge Rebound for Viking Therapeutics. Here's Why Analysts Are So Optimistic. | ||
| INTELLIA THERAPEUTICS | 10,360 | -2,08 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Secures Non-Dilutive Debt Facility with OrbiMed for up to $400 Million | CAMBRIDGE, Mass., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing... ► Artikel lesen | |
| TEMPUS AI | 67,70 | -0,09 % | Tempus AI stock is soaring: does it have more upside to go? | ||
| NUREXONE BIOLOGIC | 0,385 | -2,78 % | Bis zu 2,1 Milliarden US-Dollar: Was die Exosomen-Deals von Eli Lilly und Takeda heute für NurExone bedeuten | ||
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,209 | +1,77 % | PacBio Announces Second Quarter 2026 Financial Results | MENLO PARK, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) today announced financial results for the quarter ended June 30, 2026. Recent Business Highlights Total revenue of $39.0... ► Artikel lesen | |
| IMMUNITYBIO | 7,380 | -0,27 % | XETR NEW INSTRUMENTS AVAILABLE ON XETRA - 04.06.2026 | Folgende Wertpapiere werden in den Handel an folgenden Handelsplätzen (MIC Code) im Quotation Board an der Frankfurter Wertpapierbörse (FWB) aufgenommen. Die Notierung an anderen Handelsplätzen im Quotation... ► Artikel lesen | |
| GINKGO BIOWORKS | 6,842 | -0,35 % | Ginkgo Bioworks To Build Autonomous Lab At Novo's New U.S. R&D Site In Waltham | ||
| RECURSION PHARMACEUTICALS | 3,830 | 0,00 % | Recursion Pharmaceuticals Reports Q2 2026 Results: Full Earnings Call Transcript | ||
| IOVANCE BIOTHERAPEUTICS | 8,980 | +0,67 % | Biotech Stocks At 52-Week Highs - Nutex Health +8%, Iovance Biotherapeutics +7%, AtriCure, Centene, Concentra Group | WASHINGTON (dpa-AFX) - The following biotech stocks reached a 52-week high on September 15, 2026, driven by the gain on certain clinical or financial results.Nutex Health Inc. (NUTX)Nutex Health... ► Artikel lesen | |
| CYTOMX THERAPEUTICS | 2,420 | +0,88 % | CytomX auf Morgan Stanley Konferenz: Strategie für fortgeschrittenes Kolorektalkarzinom im Fokus | ||
| SANA BIOTECHNOLOGY | 3,100 | 0,00 % | Sana Biotechnology, Inc: Sana Biotechnology Reports Second Quarter 2026 Financial Results and Business Updates | Continued progress toward starting SC451 Phase 1/2 trial, including GLP toxicology studies, SC451 process transfer to the contract manufacturer, and clinical trial readiness Continued progress toward... ► Artikel lesen | |
| BIOMEA FUSION | 1,845 | 0,00 % | Biomea Fusion, Inc.: Biomea Fusion Announces Completion of Enrollment in COVALENT-211 Phase II Trial of Icovamenib in Insulin-Deficient Type 2 Diabetes | Topline 26-week primary endpoint data from COVALENT-211 in insulin deficient type 2 diabetes ("T2D") patients who are not achieving glycemic targets despite antihyperglycemic medications anticipated... ► Artikel lesen | |
| LIANBIO | - | - | LianMedical (Formerly Known as LianBio) Announces Completion of Merger Between LianBio and LianMedical | • Combined company to operate as LianMedical
• LianMedical to focus on advancing patient access to innovative medical technologies in China and other Asia Pacific markets
PRINCETON, N.J. & SHANGHAI--(BUSINESS... ► Artikel lesen |
Das Unternehmen FORTRESS BIOTECH INC PREF kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von +0,500 (+3,38 %) liegt der Kurs bei 15,300 Euro. Die Dividendendrendite beträgt aktuell 0,00 % (berechnet anhand der Ausschüttung von 0,00 Euro in den letzten 12 Monaten).
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu FORTRESS BIOTECH INC PREF finden Sie auf Wallstreet Online.